| Year |
Citation |
Score |
| 2023 |
Nakazawa K, Shaw T, Song YK, Kouassi-Brou M, Molotkova A, Tiwari PB, Chou HC, Wen X, Wei JS, Deniz E, Toretsky J, Keller C, Barr FG, Khan J, Üren A. Piperacetazine directly binds to the PAX3::FOXO1 fusion protein and inhibits its transcriptional activity. Cancer Research Communications. PMID 37732905 DOI: 10.1158/2767-9764.CRC-23-0119 |
0.438 |
|
| 2020 |
Ko K, Kitani T, Harris BT, Anaizi AN, Solomon D, Perry A, Toretsky J, Ozdemirli M. A novel PARD3B-NUTM1 fusion in an aggressive primary CNS embryonal tumor in a young adult. Acta Neuropathologica Communications. 8: 112. PMID 32680570 DOI: 10.1186/S40478-020-00991-W |
0.311 |
|
| 2020 |
Conn E, Hour S, Allegakoen D, Graham G, Petro J, Kouassi-Brou M, Hong SH, Selvanathan S, Çelik H, Toretsky J, Üren A. Development of an Ewing sarcoma cell line with resistance to EWS‑FLI1 inhibitor YK‑4‑279. Molecular Medicine Reports. PMID 32016454 DOI: 10.3892/Mmr.2020.10948 |
0.371 |
|
| 2019 |
Selvanathan SP, Graham GT, Grego AR, Baker TM, Hogg JR, Simpson M, Batish M, Crompton B, Stegmaier K, Tomazou EM, Kovar H, Üren A, Toretsky JA. EWS-FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex. Nucleic Acids Research. PMID 31392992 DOI: 10.1093/Nar/Gkz699 |
0.419 |
|
| 2019 |
Spriano F, Chung EYL, Gaudio E, Tarantelli C, Cascione L, Napoli S, Jessen K, Carrassa L, Priebe V, Sartori G, Graham G, Selvanathan SP, Cavalli A, Rinaldi A, Kwee I, ... ... Toretsky JA, et al. The ETS inhibitors YK-4-279 and TK-216 are novel anti-lymphoma agents. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31182435 DOI: 10.1158/1078-0432.Ccr-18-2718 |
0.456 |
|
| 2019 |
Ma Y, Baltezor M, Rajewski L, Crow J, Samuel G, Staggs VS, Chastain KM, Toretsky JA, Weir SJ, Godwin AK. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis. Journal of Molecular Medicine (Berlin, Germany). PMID 31025088 DOI: 10.1007/S00109-019-01782-0 |
0.467 |
|
| 2018 |
Anderson ND, de Borja R, Young MD, Fuligni F, Rosic A, Roberts ND, Hajjar S, Layeghifard M, Novokmet A, Kowalski PE, Anaka M, Davidson S, Zarrei M, Id Said B, Schreiner LC, ... ... Toretsky JA, et al. Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors. Science (New York, N.Y.). 361. PMID 30166462 DOI: 10.1126/Science.Aam8419 |
0.386 |
|
| 2018 |
Tsafou K, Katschnig AM, Radic-Sarikas B, Mutz CN, Iljin K, Schwentner R, Kauer MO, Mühlbacher K, Aryee DNT, Westergaard D, Haapa-Paananen S, Fey V, Superti-Furga G, Toretsky J, Brunak S, et al. Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers. Oncotarget. 9: 31018-31031. PMID 30123424 DOI: 10.18632/Oncotarget.25760 |
0.435 |
|
| 2018 |
Tsafou K, Tiwari PB, Forman-Kay JD, Metallo SJ, Toretsky JA. Targeting intrinsically disordered transcription factors: Changing the paradigm. Journal of Molecular Biology. PMID 29655986 DOI: 10.1016/J.Jmb.2018.04.008 |
0.361 |
|
| 2018 |
Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, Iniguez AB, Bernard X, Masamsetti VP, Roston S, Lawlor ER, Toretsky JA, Stegmaier K, Lessnick SL, Chen Y, et al. EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature. PMID 29513652 DOI: 10.1038/Nature25748 |
0.416 |
|
| 2018 |
Çelik H, Sciandra M, Flashner B, Gelmez E, Kayraklıoğlu N, Allegakoen DV, Petro JR, Conn EJ, Hour S, Han J, Oktay L, Tiwari PB, Hayran M, Harris BT, Manara MC, ... Toretsky JA, et al. Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99. Oncogene. PMID 29382926 DOI: 10.1038/S41388-017-0080-4 |
0.387 |
|
| 2017 |
Zöllner SK, Selvanathan SP, Graham GT, Commins RMT, Hong SH, Moseley E, Parks S, Haladyna JN, Erkizan HV, Dirksen U, Hogarty MD, Üren A, Toretsky JA. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma. Science Signaling. 10. PMID 28974650 DOI: 10.1126/Scisignal.Aam8429 |
0.487 |
|
| 2017 |
Radic-Sarikas B, Tsafou KP, Emdal KB, Papamarkou T, Huber KV, Mutz C, Toretsky JA, Bennett KL, Olsen JV, Brunak S, Kovar H, Superti-Furga G. Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities. Molecular Cancer Therapeutics. 16: 88-101. PMID 28062706 DOI: 10.1158/1535-7163.Mct-16-0235 |
0.424 |
|
| 2017 |
Federman N, Meyers PA, Daw NC, Toretsky J, Breitmeyer JB, Singh AS, Miller LL, Oltersdorf T, Jezior D, Jessen KA, Lannutti B, Ludwig JA. A phase I, first-in-human, dose escalation study of intravenous TK216 in patients with relapsed or refractory Ewing sarcoma. Journal of Clinical Oncology. 35: TPS11626-TPS11626. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps11626 |
0.405 |
|
| 2017 |
Selvanathan SP, Moseley E, Graham GT, Jessen K, Lannutti B, Üren A, Toretsky JA. Abstract 694: TK-216: a novel, first-in-class, small molecule inhibitor of EWS-FLI1 in early clinical development, for the treatment of Ewing Sarcoma Cancer Research. 77: 694-694. DOI: 10.1158/1538-7445.Am2017-694 |
0.477 |
|
| 2017 |
Spriano F, Tarantelli C, Gaudio E, Chung EY, Arribas AJ, Cascione L, Napoli S, Kwee I, Rinaldi A, Rossi D, Zucca E, Stathis A, Jessen K, Lannutti B, Toretsky J, et al. Abstract 5179: The first in class FLI1 inhibitor TK-216 presents both in vitro and in vivo anti-tumor activity in lymphoma Cancer Research. 77: 5179-5179. DOI: 10.1158/1538-7445.Am2017-5179 |
0.429 |
|
| 2017 |
Celik H, Sciandra M, Flashner B, Gelmez E, Kayraklıoğlu N, Allegakoen DV, Petro JR, Conn EJ, Hour S, Han J, Oktay L, Tiwari PB, Hayran M, Manara MC, Toretsky JA, et al. Abstract 1933: Discovery of first-in-class small molecule CD99 inhibitors for targeted therapy of Ewing sarcoma Cancer Research. 77: 1933-1933. DOI: 10.1158/1538-7445.Am2017-1933 |
0.399 |
|
| 2016 |
Minas TZ, Surdez D, Javaheri T, Tanaka M, Howarth M, Kang HJ, Han J, Han ZY, Sax B, Kream BE, Hong SH, Çelik H, Tirode F, Tuckermann J, Toretsky JA, et al. Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget. PMID 27191748 DOI: 10.18632/Oncotarget.9388 |
0.393 |
|
| 2016 |
Celik H, Bulut G, Han J, Graham GT, Minas TZ, Conn EJ, Hong SH, Pauly GT, Hayran M, Li X, Özdemirli M, Ayhan A, Rudek MA, Toretsky JA, Üren A. Ezrin Inhibition Upregulates Stress Response Gene Expression. The Journal of Biological Chemistry. PMID 27137931 DOI: 10.1074/Jbc.M116.718189 |
0.365 |
|
| 2016 |
Saygideğer-Kont Y, Minas TZ, Jones H, Hour S, Çelik H, Temel I, Han J, Atabey N, Erkizan HV, Toretsky JA, Üren A. Ezrin Enhances EGFR Signaling and Modulates Erlotinib Sensitivity in Non-Small Cell Lung Cancer Cells. Neoplasia (New York, N.Y.). 18: 111-20. PMID 26936397 DOI: 10.1016/J.Neo.2016.01.002 |
0.369 |
|
| 2016 |
Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, ... ... Toretsky J, et al. The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget. PMID 26802024 DOI: 10.18632/Oncotarget.6937 |
0.388 |
|
| 2016 |
Jessen K, Moseley E, Chung EYL, Otuski L, Tarantelli C, Gaudio E, Breitmeyer J, Freddo J, Toretsky J, Bertoni F, Lannutti BJ. TK216, a Novel, Small Molecule Inhibitor of the ETS-Family of Transcription Factors, Displays Anti-Tumor Activity in AML and DLBCL Blood. 128: 4035-4035. DOI: 10.1182/Blood.V128.22.4035.4035 |
0.449 |
|
| 2016 |
Toretsky J, Graham G, Dirksen U, Erkizan HV, Lawlor E, Uren A, Selvanathan S. Abstract A39: Alternative splicing in Ewing sarcoma may be driven by phase separation of spliceosome proteins Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-A39 |
0.504 |
|
| 2016 |
Çelik H, Bulut G, Han J, Graham GT, Minas TZ, Conn EJ, Hong S, Pauly GT, Hayran M, Li X, Özdemirli M, Ayhan A, Rudek MA, Toretsky JA, Üren A. Abstract 2446: Ezrin inhibition up-regulates stress response gene expression and blocks osteosarcoma metastasis Cancer Research. 76: 2446-2446. DOI: 10.1158/1538-7445.Am2016-2446 |
0.444 |
|
| 2015 |
Minas TZ, Han J, Javaheri T, Hong SH, Schlederer M, Saygideğer-Kont Y, Çelik H, Mueller KM, Temel I, Özdemirli M, Kovar H, Erkizan HV, Toretsky J, Kenner L, Moriggl R, et al. YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model. Oncotarget. PMID 26462019 DOI: 10.18632/Oncotarget.5520 |
0.415 |
|
| 2015 |
Celik H, Hong SH, Colón-López DD, Han J, Saygideger Kont Y, Minas TZ, Swift M, Paige M, Glasgow E, Toretsky JA, Bosch J, Uren A. Identification of novel ezrin inhibitors targeting metastatic osteosarcoma by screening open access malaria box. Molecular Cancer Therapeutics. PMID 26358752 DOI: 10.1158/1535-7163.Mct-15-0511 |
0.432 |
|
| 2015 |
Zöllner SK, Rössig C, Toretsky JA. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer. Cancer Metastasis Reviews. 34: 417-28. PMID 26277104 DOI: 10.1007/S10555-015-9575-Z |
0.447 |
|
| 2015 |
Çelik H, Sajwan KP, Selvanathan SP, Marsh BJ, Pai AV, Kont YS, Han J, Minas TZ, Rahim S, Erkizan HV, Toretsky JA, Üren A. Ezrin Binds to DEAD-Box RNA Helicase DDX3 and Regulates Its Function and Protein Level. Molecular and Cellular Biology. 35: 3145-62. PMID 26149384 DOI: 10.1128/Mcb.00332-15 |
0.449 |
|
| 2015 |
Selvanathan SP, Graham GT, Erkizan HV, Dirksen U, Natarajan TG, Dakic A, Yu S, Liu X, Paulsen MT, Ljungman ME, Wu CH, Lawlor ER, Üren A, Toretsky JA. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing. Proceedings of the National Academy of Sciences of the United States of America. 112: E1307-16. PMID 25737553 DOI: 10.1073/Pnas.1500536112 |
0.416 |
|
| 2015 |
Hong SH, Tilan JU, Galli S, Izycka-Swieszewska E, Polk T, Horton M, Mahajan A, Christian D, Jenkins S, Acree R, Connors K, Ledo P, Lu C, Lee YC, Rodriguez O, ... Toretsky JA, et al. High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases. Oncotarget. 6: 7151-65. PMID 25714031 DOI: 10.18632/Oncotarget.3345 |
0.328 |
|
| 2015 |
Erkizan HV, Schneider JA, Sajwan K, Graham GT, Griffin B, Chasovskikh S, Youbi SE, Kallarakal A, Chruszcz M, Padmanabhan R, Casey JL, Üren A, Toretsky JA. RNA helicase A activity is inhibited by oncogenic transcription factor EWS-FLI1. Nucleic Acids Research. 43: 1069-80. PMID 25564528 DOI: 10.1093/Nar/Gku1328 |
0.415 |
|
| 2015 |
Tilan JU, Krailo M, Barkauskas DA, Galli S, Mtaweh H, Long J, Wang H, Hawkins K, Lu C, Jeha D, Izycka-Swieszewska E, Lawlor ER, Toretsky JA, Kitlinska JB. Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival. Cancer. 121: 697-707. PMID 25387699 DOI: 10.1002/Cncr.29090 |
0.436 |
|
| 2015 |
Minas TZ, Han J, Javaheri T, Hong SH, Schlederer M, Saygideger-Kont Y, Çelik H, Mueller KM, Temel I, Özdemirli M, Kovar H, Erkizan HV, Toretsky J, Kenner L, Moriggl R, et al. YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model Oncotarget. 6: 37678-37694. DOI: 10.18632/oncotarget.5520 |
0.302 |
|
| 2015 |
Kont YS, Celik H, Erkizan HV, Minas T, Han J, Toretsky J, Uren A. Abstract 54: Ezrin enhances signaling and nuclear translocation of the epidermal growth factor receptor in non-small cell lung cancer cells Cancer Research. 75: 54-54. DOI: 10.1158/1538-7445.Am2015-54 |
0.386 |
|
| 2015 |
Zöllner SK, Commins R, Hong SH, Erkizan HV, Toretsky JA. Abstract 485: EWS-FLI1 targeted small molecule YK-4-279 synergizes with vinca alkaloids through double hit to mitotic machinery Cancer Research. 75: 485-485. DOI: 10.1158/1538-7445.Am2015-485 |
0.459 |
|
| 2015 |
Minas TZ, Han J, Hong S, Javaheri T, Schlederer M, Kenner L, Moriggl R, Toretsky J, Uren A. Abstract 3284: Unfavorable outcomes of EWS-FLI1 expression in different tissues of a transgenic mouse model Cancer Research. 75: 3284-3284. DOI: 10.1158/1538-7445.Am2015-3284 |
0.306 |
|
| 2015 |
Celik H, Sajwan KP, Pai AV, Marsh BJ, Kont YS, Rahim S, Han J, Minas T, Toretsky JA, Uren A. Abstract 3269: Ezrin binds to DEAD-box RNA helicase DDX3 and regulates its function and protein level Cancer Research. 75: 3269-3269. DOI: 10.1158/1538-7445.Am2015-3269 |
0.361 |
|
| 2015 |
Chung EY, Priebe V, Gaudio E, Kwee I, Tarantelli C, Rinaldi A, Carrassa L, Testoni M, Cascione L, Broggini M, Toretsky JA, Zucca E, Bertoni F. Abstract 1654: The small molecule YK-4-279 shows anti-lymphoma activity in pre-clinical models Cancer Research. 75: 1654-1654. DOI: 10.1158/1538-7445.Am2015-1654 |
0.42 |
|
| 2014 |
Rahim S, Minas T, Hong SH, Justvig S, Çelik H, Kont YS, Han J, Kallarakal AT, Kong Y, Rudek MA, Brown ML, Kallakury B, Toretsky JA, Üren A. A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model. Plos One. 9: e114260. PMID 25479232 DOI: 10.1371/Journal.Pone.0114260 |
0.37 |
|
| 2014 |
Tosso PN, Kong Y, Scher L, Cummins R, Schneider J, Rahim S, Holman KT, Toretsky J, Wang K, Ãœren A, Brown ML. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma. Journal of Medicinal Chemistry. 57: 10290-303. PMID 25432018 DOI: 10.1021/Jm501372P |
0.444 |
|
| 2014 |
Toretsky JA, Wright PE. Assemblages: functional units formed by cellular phase separation. The Journal of Cell Biology. 206: 579-88. PMID 25179628 DOI: 10.1083/Jcb.201404124 |
0.309 |
|
| 2014 |
Shah N, Wang J, Selich-Anderson J, Graham G, Siddiqui H, Li X, Khan J, Toretsky J. PBX1 is a favorable prognostic biomarker as it modulates 13-cis retinoic acid-mediated differentiation in neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4400-12. PMID 24947929 DOI: 10.1158/1078-0432.Ccr-13-1486 |
0.332 |
|
| 2014 |
Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, Chetram M, Joshi M, Wang F, Kallakury B, Toretsky J, et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Science Signaling. 7: ra42. PMID 24803537 DOI: 10.1126/Scisignal.2005049 |
0.403 |
|
| 2014 |
Hong SH, Youbi SE, Hong SP, Kallakury B, Monroe P, Erkizan HV, Barber-Rotenberg JS, Houghton P, Ãœren A, Toretsky JA. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma. Oncotarget. 5: 338-50. PMID 24481407 DOI: 10.18632/Oncotarget.1495 |
0.797 |
|
| 2014 |
Paige M, Kosturko G, Bulut G, Miessau M, Rahim S, Toretsky JA, Brown ML, Üren A. Design, synthesis and biological evaluation of ezrin inhibitors targeting metastatic osteosarcoma. Bioorganic & Medicinal Chemistry. 22: 478-87. PMID 24326277 DOI: 10.1016/J.Bmc.2013.11.003 |
0.423 |
|
| 2014 |
Minas TZ, Han J, Hong S, Toretsky J, Uren A. Abstract LB-197: YK-4-279 is effective in treating EWS-FLI1 induced myeloid/erythroid leukemia in a transgenic mouse model Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-197 |
0.373 |
|
| 2014 |
Celik H, Kallarakal A, Colon-Lopez D, Toretsky J, Bosch J, Uren A. Abstract 3987: Evaluation of anti–malarial compounds as inhibitors of ezrin in osteosarcoma cells Cancer Research. 74: 3987-3987. DOI: 10.1158/1538-7445.Am2014-3987 |
0.433 |
|
| 2014 |
Celik H, Han J, Hong S, Bulut G, Toretsky J, Uren A. Abstract 3979: NSC305787 inhibits specific protein–protein interactions involving ezrin in osteosarcoma cells Cancer Research. 74: 3979-3979. DOI: 10.1158/1538-7445.Am2014-3979 |
0.478 |
|
| 2014 |
Rahim S, Justvig S, Hong S, Tosso P, Celik H, Sayedigar-Kont Y, Brown M, Morrissey C, Toretsky J, Üren A. Abstract 2949: YK-4-279 is a small molecule inhibitor of ETV1 and inhibits metastasis in a mouse model Cancer Research. 74: 2949-2949. DOI: 10.1158/1538-7445.Am2014-2949 |
0.446 |
|
| 2013 |
Tilan JU, Lu C, Galli S, Izycka-Swieszewska E, Earnest JP, Shabbir A, Everhart LM, Wang S, Martin S, Horton M, Mahajan A, Christian D, O'Neill A, Wang H, Zhuang T, ... ... Toretsky JA, et al. Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth-inhibitory to growth-promoting effects. Oncotarget. 4: 2487-501. PMID 24318733 DOI: 10.18632/Oncotarget.1604 |
0.402 |
|
| 2013 |
Lee HJ, Yoon C, Schmidt B, Park do J, Zhang AY, Erkizan HV, Toretsky JA, Kirsch DG, Yoon SS. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage. Molecular Cancer Therapeutics. 12: 2591-600. PMID 23966622 DOI: 10.1158/1535-7163.Mct-13-0338 |
0.343 |
|
| 2013 |
O'Neill A, Shah N, Zitomersky N, Ladanyi M, Shukla N, Uren A, Loeb D, Toretsky J. Insulin-like growth factor 1 receptor as a therapeutic target in ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature. Sarcoma. 2013: 450478. PMID 23431249 DOI: 10.1155/2013/450478 |
0.353 |
|
| 2013 |
Abaan OD, Hendriks W, Uren A, Toretsky JA, Erkizan HV. Valosin containing protein (VCP/p97) is a novel substrate for the protein tyrosine phosphatase PTPL1. Experimental Cell Research. 319: 1-11. PMID 23018179 DOI: 10.1016/J.Yexcr.2012.09.003 |
0.439 |
|
| 2013 |
Toretsky J, Gamble SE, Monroe PJ, Hong SP, Summer SJ, Uren A, Hong S. Effect of a novel small molecule yk-4-279 on the "undruggable" target EWS-FLI1. Journal of Clinical Oncology. 31: 10042-10042. DOI: 10.1200/Jco.2013.31.15_Suppl.10042 |
0.466 |
|
| 2013 |
Rahim S, Justvig S, Hong S, Kong Y, Brown ML, Morrissey C, Toretsky JA, Uren A. Abstract 5453: YK-4-279 inhibits ETS-positive prostate cancer cell metastasis in a mouse xenograft model. Cancer Research. 73: 5453-5453. DOI: 10.1158/1538-7445.Am2013-5453 |
0.368 |
|
| 2013 |
Erkizan HV, Sajwan K, Chruszcz M, Schneider J, Gamble SE, Uren A, Minor W, Padmanabhan R, Toretsky J. Abstract 2747: EWS-FLI1 reduces RNA Helicase A activity. Cancer Research. 73: 2747-2747. DOI: 10.1158/1538-7445.Am2013-2747 |
0.429 |
|
| 2012 |
Kirilyuk A, Shimoji M, Catania J, Sahu G, Pattabiraman N, Giordano A, Albanese C, Mocchetti I, Toretsky JA, Uversky VN, Avantaggiati ML. An intrinsically disordered region of the acetyltransferase p300 with similarity to prion-like domains plays a role in aggregation. Plos One. 7: e48243. PMID 23133622 DOI: 10.1371/Journal.Pone.0048243 |
0.345 |
|
| 2012 |
Schlottmann S, Erkizan HV, Barber-Rotenberg JS, Knights C, Cheema A, Uren A, Avantaggiati ML, Toretsky JA. Acetylation Increases EWS-FLI1 DNA Binding and Transcriptional Activity. Frontiers in Oncology. 2: 107. PMID 22973553 DOI: 10.3389/Fonc.2012.00107 |
0.781 |
|
| 2012 |
Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PC, ... ... Toretsky J, et al. The first European interdisciplinary ewing sarcoma research summit. Frontiers in Oncology. 2: 54. PMID 22662320 DOI: 10.3389/Fonc.2012.00054 |
0.303 |
|
| 2012 |
Barber-Rotenberg JS, Selvanathan SP, Kong Y, Erkizan HV, Snyder TM, Hong SP, Kobs CL, South NL, Summer S, Monroe PJ, Chruszcz M, Dobrev V, Tosso PN, Scher LJ, Minor W, ... ... Toretsky JA, et al. Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget. 3: 172-82. PMID 22383402 DOI: 10.18632/Oncotarget.454 |
0.79 |
|
| 2012 |
Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW, Glasgow E, Dakshanamurthy S, Lee HS, Daar I, Toretsky JA, Khanna C, Uren A. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene. 31: 269-81. PMID 21706056 DOI: 10.1038/Onc.2011.245 |
0.351 |
|
| 2012 |
Toretsky J, Hong SP, Gamble SE, Hong S, Kobs CL, Elsass KE, South NL, Summer SJ, Monroe PJ, Uren A. Use of pharmacokinetic modeling to optimize direct inhibition of the "undruggable" target EWS-FLI1 of Ewing sarcoma. Journal of Clinical Oncology. 30: 9575-9575. DOI: 10.1200/Jco.2012.30.15_Suppl.9575 |
0.427 |
|
| 2012 |
Hong SP, Gamble SE, Hong S, Kobs CL, Elsass KE, South NL, Monroe PJ, Üren A, Toretsky JA. Abstract LB-316: Pharmacokinetic modeling optimizes direct inhibition of the ‘undruggable’ target EWS-FLI1 of Ewing Sarcoma Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-316 |
0.439 |
|
| 2012 |
Murdoch JT, Hong S, Bulut G, Kosturko GW, Drebing LE, Toretsky JA, Uren A. Abstract 4874: Small molecule inhibitor of ezrin inhibits metastasis in a transgenic mouse model of osteosarcoma Cancer Research. 72: 4874-4874. DOI: 10.1158/1538-7445.Am2012-4874 |
0.333 |
|
| 2012 |
Tilan JU, Lu C, Earnest JP, Everhart LM, Shabir A, O'Neill A, Wang S, Czarnecka M, Toretsky JA, Kitlinska J. Abstract 3950: Differential functions of neuropeptide Y in Ewing's sarcoma - hypoxia as a switch Cancer Research. 72: 3950-3950. DOI: 10.1158/1538-7445.Am2012-3950 |
0.427 |
|
| 2012 |
Kosturko GW, Bulut G, Hong S, Rodriguez V, Brown M, Toretsky J, Khanna C, Paige M, Uren A. Abstract 3906: Design, synthesis and biological evaluation of 2nd generation ezrin inhibitors for metastatic osteosarcoma Cancer Research. 72: 3906-3906. DOI: 10.1158/1538-7445.Am2012-3906 |
0.426 |
|
| 2011 |
Erkizan HV, Scher LJ, Gamble SE, Barber-Rotenberg JS, Sajwan KP, Üren A, Toretsky JA. Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors. Cell Cycle (Georgetown, Tex.). 10: 3397-408. PMID 21926473 DOI: 10.4161/Cc.10.19.17734 |
0.792 |
|
| 2011 |
Ringer L, Sirajuddin P, Heckler M, Ghosh A, Suprynowicz F, Yenugonda VM, Brown ML, Toretsky JA, Uren A, Lee Y, MacDonald TJ, Rodriguez O, Glazer RI, Schlegel R, Albanese C. VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. Cancer Biology & Therapy. 12: 818-26. PMID 21885916 DOI: 10.4161/Cbt.12.9.17682 |
0.381 |
|
| 2011 |
Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, Toretsky JA, Rosenberg SA, Shukla N, Ladanyi M, Samuels Y, James CD, Yu H, Kim JS, Waldman T. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (New York, N.Y.). 333: 1039-43. PMID 21852505 DOI: 10.1126/Science.1203619 |
0.347 |
|
| 2011 |
Lu C, Tilan JU, Everhart L, Czarnecka M, Soldin SJ, Mendu DR, Jeha D, Hanafy J, Lee CK, Sun J, Izycka-Swieszewska E, Toretsky JA, Kitlinska J. Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors: implications for tumor biology and therapy. The Journal of Biological Chemistry. 286: 27494-505. PMID 21680731 DOI: 10.1074/Jbc.M111.224089 |
0.452 |
|
| 2011 |
Rahim S, Beauchamp EM, Kong Y, Brown ML, Toretsky JA, Üren A. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. Plos One. 6: e19343. PMID 21559405 DOI: 10.1371/Journal.Pone.0019343 |
0.309 |
|
| 2011 |
Wellstein A, Toretsky JA. Hunting ALK to feed targeted cancer therapy. Nature Medicine. 17: 290-1. PMID 21383740 DOI: 10.1038/Nm0311-290 |
0.314 |
|
| 2011 |
Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, Peaceman D, Ozdemirli M, Rodriguez O, Macdonald TJ, Albanese C, Toretsky JA, Uren A. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. The Journal of Clinical Investigation. 121: 148-60. PMID 21183792 DOI: 10.1172/Jci42874 |
0.46 |
|
| 2011 |
Rahim S, Beauchamp EM, Kong Y, Brown ML, Toretsky JA, Üren A. Abstract 663: YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion Cancer Research. 71: 663-663. DOI: 10.1158/1538-7445.Am2011-663 |
0.369 |
|
| 2011 |
Bulut G, Hong S, Chen K, Rahim S, Kosturko GW, Beauchamp EM, Glasgow E, Toretsky JA, Khanna C, Uren A. Abstract 4505: Development of small molecules to target ezrin as anti-metastatic agents Cancer Research. 71: 4505-4505. DOI: 10.1158/1538-7445.Am2011-4505 |
0.494 |
|
| 2011 |
Tilan JU, Mtaweh H, Everhart LM, Long J, Barkauskas DA, Krailo M, Jeha D, Toretsky J, Kitlinska J. Abstract 4352: Systemic levels of neuropeptide Y are elevated in Ewing's sarcoma patients Cancer Research. 71: 4352-4352. DOI: 10.1158/1538-7445.Am2011-4352 |
0.347 |
|
| 2011 |
Erkizan HV, Scher LM, Gamble E, Barber-Rotenberg J, Uren A, Toretsky J. Abstract 259: Novel peptide directed targeting of EWS-FLI1 impairs tumor cell growth Cancer Research. 71: 259-259. DOI: 10.1158/1538-7445.Am2011-259 |
0.759 |
|
| 2011 |
Lu C, Everhart L, Tilan JU, Czarnecka M, Hanafy J, Jeha D, Toretsky JA, Kitlinska JB. Abstract 187: Dipeptidyl peptidases abolish growth inhibitory effect of neuropeptide Y in Ewing's sarcoma family of tumors Cancer Research. 71: 187-187. DOI: 10.1158/1538-7445.Am2011-187 |
0.471 |
|
| 2010 |
Awad O, Yustein JT, Shah P, Gul N, Katuri V, O'Neill A, Kong Y, Brown ML, Toretsky JA, Loeb DM. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. Plos One. 5: e13943. PMID 21085683 DOI: 10.1371/Journal.Pone.0013943 |
0.343 |
|
| 2010 |
Lu C, Everhart L, Tilan J, Kuo L, Sun CCJ, Munivenkatappa RB, Jönsson-Rylander AC, Sun J, Kuan-Celarier A, Li L, Abe K, Zukowska Z, Toretsky JA, Kitlinska J. Neuropeptide y and its Y2 receptor: Potential targets in neuroblastoma therapy Oncogene. 29: 5630-5642. PMID 20676138 DOI: 10.1038/Onc.2010.301 |
0.452 |
|
| 2010 |
Erkizan HV, Uversky VN, Toretsky JA. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4077-83. PMID 20547696 DOI: 10.1158/1078-0432.Ccr-09-2261 |
0.505 |
|
| 2010 |
Awad O, Yustein JT, Shah P, Gul N, Rotenberg JB, Toretsky J, Loeb D. Abstract 4274: High aldehyde dehydrogenase activity identifies a chemotherapy-resistant population of ewing's sarcoma cells with a stem cell phenotype that retains sensitivity to EWS-FLI1 inhibition Cancer Research. 70: 4274-4274. DOI: 10.1158/1538-7445.Am10-4274 |
0.435 |
|
| 2010 |
Schlottmann S, Erkizan HV, Barber-Rotenberg J, Uren A, Avantaggiati ML, Toretsky JA. Abstract 3897: EWS-FLI1 is regulated by acetylation Cancer Research. 70: 3897-3897. DOI: 10.1158/1538-7445.Am10-3897 |
0.792 |
|
| 2010 |
Jacobwitz LM, Erkizan HV, Üren A, Toretsky JA. Abstract 3412: Phage display identifies novel toxic binding peptides for the disordered oncoprotein EWS-FLI1 Cancer Research. 70: 3412-3412. DOI: 10.1158/1538-7445.Am10-3412 |
0.459 |
|
| 2010 |
Toretsky JA, Erkizan HV, Kong Y, Merchant M, Barber-Rotenberg JS, Brown ML, Üren A. Abstract 3411: Targeting of EWS-FLI1 with small molecule YK-4-279 reduces xenograft growth by disruption of disordered protein-protein interactions Cancer Research. 70: 3411-3411. DOI: 10.1158/1538-7445.Am10-3411 |
0.794 |
|
| 2010 |
Beauchamp EM, Rodriguez O, Albanese C, Toretsky JA, Üren A. Abstract 3409: Arsenic trioxide inhibits Ewing sarcoma growth by blocking Hedgehog/GLI pathway Cancer Research. 70: 3409-3409. DOI: 10.1158/1538-7445.Am10-3409 |
0.477 |
|
| 2010 |
Barber-Rotenberg JS, Kong Y, Schnure N, Dakshanamurthy S, Frazier P, Erkizan HV, Brown ML, Uren A, Toretsky JA. Abstract 2681: EWS-FLI1 as a molecular target: Small molecule inhibitors for a disordered protein Cancer Research. 70: 2681-2681. DOI: 10.1158/1538-7445.Am10-2681 |
0.78 |
|
| 2010 |
Bulut G, Chen K, Glasgow E, Hong S, Lee H, Kosturko G, Toretsky JA, Daar I, Khanna C, Uren A. Abstract 1550: Small molecule inhibitors of ezrin as anti-metastatic agents in osteosarcoma Cancer Research. 70: 1550-1550. DOI: 10.1158/1538-7445.Am10-1550 |
0.449 |
|
| 2009 |
Stylianou DC, Auf der Maur A, Kodack DP, Henke RT, Hohn S, Toretsky JA, Riegel AT, Wellstein A. Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. Oncogene. 28: 3296-306. PMID 19633684 DOI: 10.1038/Onc.2009.184 |
0.415 |
|
| 2009 |
Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, Abaan OD, Chou TH, Dakshanamurthy S, Brown ML, Uren A, Toretsky JA. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nature Medicine. 15: 750-6. PMID 19584866 DOI: 10.1038/Nm.1983 |
0.805 |
|
| 2009 |
Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, Matsui W, Endo Y, Rubin JS, Toretsky J, Uren A. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. The Journal of Biological Chemistry. 284: 9074-82. PMID 19189974 DOI: 10.1074/Jbc.M806233200 |
0.482 |
|
| 2009 |
Kim SY, Toretsky JA, Scher D, Helman LJ. The role of IGF-1R in pediatric malignancies. The Oncologist. 14: 83-91. PMID 19126579 DOI: 10.1634/Theoncologist.2008-0189 |
0.305 |
|
| 2009 |
Barber‐Rotenberg JS, Kong Y, Schnure N, Dakshanamurthy S, Frazier P, Erkizan HV, Brown ML, Üren A, Toretsky JA. Abstract B181: EWS‐FLI1 as a molecular target: Identification of inhibitors for a disordered protein Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B181 |
0.464 |
|
| 2008 |
Chen K, Fallen S, Abaan HO, Hayran M, Gonzalez C, Wodajo F, MacDonald T, Toretsky JA, Uren A. Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatric Blood & Cancer. 51: 349-55. PMID 18465804 DOI: 10.1002/Pbc.21595 |
0.308 |
|
| 2008 |
Abaan OD, Toretsky JA. PTPL1: a large phosphatase with a split personality. Cancer Metastasis Reviews. 27: 205-14. PMID 18265946 DOI: 10.1007/S10555-008-9114-2 |
0.407 |
|
| 2008 |
Endo Y, Beauchamp E, Woods D, Taylor WG, Toretsky JA, Uren A, Rubin JS. Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells via a Frizzled3- and c-Jun N-terminal kinase-dependent mechanism. Molecular and Cellular Biology. 28: 2368-79. PMID 18212053 DOI: 10.1128/Mcb.01780-07 |
0.39 |
|
| 2008 |
French CA, Ramirez CL, Kolmakova J, Hickman TT, Cameron MJ, Thyne ME, Kutok JL, Toretsky JA, Tadavarthy AK, Kees UR, Fletcher JA, Aster JC. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene. 27: 2237-42. PMID 17934517 DOI: 10.1038/Sj.Onc.1210852 |
0.416 |
|
| 2006 |
Aryee DN, Kreppel M, Bachmaier R, Uren A, Muehlbacher K, Wagner S, Breiteneder H, Ban J, Toretsky JA, Kovar H. Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo. Cancer Research. 66: 9862-9. PMID 17047047 DOI: 10.1158/0008-5472.Can-05-4042 |
0.439 |
|
| 2006 |
Toretsky JA, Erkizan V, Levenson A, Abaan OD, Parvin JD, Cripe TP, Rice AM, Lee SB, Uren A. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Research. 66: 5574-81. PMID 16740692 DOI: 10.1158/0008-5472.Can-05-3293 |
0.51 |
|
| 2005 |
Uren A, Toretsky JA. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent. Future Oncology (London, England). 1: 521-8. PMID 16556028 DOI: 10.2217/14796694.1.4.521 |
0.461 |
|
| 2005 |
Abaan OD, Levenson A, Khan O, Furth PA, Uren A, Toretsky JA. PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis. Oncogene. 24: 2715-22. PMID 15782144 DOI: 10.1038/Sj.Onc.1208247 |
0.517 |
|
| 2005 |
Kitlinska J, Abe K, Kuo L, Pons J, Yu M, Li L, Tilan J, Everhart L, Lee EW, Zukowska Z, Toretsky JA. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Research. 65: 1719-28. PMID 15753367 DOI: 10.1158/0008-5472.Can-04-2192 |
0.39 |
|
| 2005 |
Uren A, Toretsky JA. Pediatric malignancies provide unique cancer therapy targets. Current Opinion in Pediatrics. 17: 14-9. PMID 15659957 DOI: 10.1097/01.Mop.0000147904.84978.Ae |
0.412 |
|
| 2005 |
Toretsky J, Levenson A, Weinberg IN, Tait JF, Uren A, Mease RC. Preparation of F-18 labeled annexin V: a potential PET radiopharmaceutical for imaging cell death. Nuclear Medicine and Biology. 31: 747-52. PMID 15246365 DOI: 10.1016/J.Nucmedbio.2004.02.007 |
0.321 |
|
| 2004 |
Uren A, Tcherkasskaya O, Toretsky JA. Recombinant EWS-FLI1 oncoprotein activates transcription. Biochemistry. 43: 13579-89. PMID 15491164 DOI: 10.1021/Bi048776Q |
0.479 |
|
| 2004 |
Uren A, Wolf V, Sun YF, Azari A, Rubin JS, Toretsky JA. Wnt/Frizzled signaling in Ewing sarcoma. Pediatric Blood & Cancer. 43: 243-9. PMID 15266408 DOI: 10.1002/Pbc.20124 |
0.342 |
|
| 2003 |
Gober MD, Smith CC, Ueda K, Toretsky JA, Aurelian L. Forced expression of the H11 heat shock protein can be regulated by DNA methylation and trigger apoptosis in human cells. The Journal of Biological Chemistry. 278: 37600-9. PMID 12832417 DOI: 10.1074/Jbc.M303834200 |
0.368 |
|
| 2003 |
Uren A, Merchant MS, Sun CJ, Vitolo MI, Sun Y, Tsokos M, Illei PB, Ladanyi M, Passaniti A, Mackall C, Toretsky JA. Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene. 22: 2334-42. PMID 12700668 DOI: 10.1038/Sj.Onc.1206330 |
0.374 |
|
| 2001 |
Merino ME, Navid F, Christensen BL, Toretsky JA, Helman LJ, Cheung NKV, Mackall CL. Immunomagnetic purging of Ewing's sarcoma from blood and bone marrow: Quantitation by real-time polymerase chain reaction Journal of Clinical Oncology. 19: 3649-3659. PMID 11504746 DOI: 10.1200/Jco.2001.19.16.3649 |
0.331 |
|
| 1997 |
Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts Journal of Biological Chemistry. 272: 30822-30827. PMID 9388225 DOI: 10.1074/Jbc.272.49.30822 |
0.395 |
|
| 1997 |
Toretsky JA, Helman LJ. Cytogenetics and experimental models Current Opinion in Oncology. 9: 342-347. PMID 9251884 DOI: 10.1097/00001622-199709040-00007 |
0.373 |
|
| 1997 |
Schulte TW, Toretsky JA, Ress E, Helman L, Neckers LM. Expression of PAX3 in Ewing's sarcoma family of tumors Biochemical and Molecular Medicine. 60: 121-126. PMID 9169092 DOI: 10.1006/Bmme.1997.2567 |
0.369 |
|
| 1997 |
Toretsky JA, Connell Y, Neckers L, Bhat NK. Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides Journal of Neuro-Oncology. 31: 9-16. PMID 9049825 DOI: 10.1023/A:1005716926800 |
0.459 |
|
| 1996 |
Blagosklonny MV, Toretsky J, Bohen S, Neckers L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proceedings of the National Academy of Sciences of the United States of America. 93: 8379-83. PMID 8710879 DOI: 10.1073/Pnas.93.16.8379 |
0.301 |
|
| 1996 |
Toretsky JA, Helman LJ. Involvement of IGF-II in human cancer Journal of Endocrinology. 149: 367-372. PMID 8691094 DOI: 10.1677/Joe.0.1490367 |
0.336 |
|
| 1995 |
Rosolen A, Frascella E, Toretsky J, Neckers L. Episome generated C-myc antisense RNA inhibits growth and tumorigenicity of a human neuroendocrine tumor-cell line. International Journal of Oncology. 6: 175-179. PMID 21556520 DOI: 10.3892/Ijo.6.1.175 |
0.384 |
|
| 1995 |
Toretsky JA, Neckers L, Wexler LH. Detection of (11; 22)(q24;q12) translocation-bearing cells in peripheral blood progenitor cells of patients with ewing's sarcoma family of tumors Journal of the National Cancer Institute. 87: 385-386. PMID 7853420 DOI: 10.1093/Jnci/87.5.385 |
0.327 |
|
| Show low-probability matches. |